Drug Profile

GPD 1116

Alternative Names: GPD-1116

Latest Information Update: 23 Jun 2015

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ASKA Pharmaceutical
Class Antiallergics; Antiasthmatics; Naphthyridines
Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Allergic asthma; Chronic obstructive pulmonary disease

Most Recent Events

23 Jun 2015 No recent reports on development identified - Phase-I for Allergic asthma in Germany (PO)
23 Jun 2015 No recent reports on development identified - Phase-II for Allergic asthma in United Kingdom (PO)
23 Jun 2015 No recent reports on development identified - Preclinical for Chronic obstructive pulmonary disease in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com